Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 03, 5:44PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 5.83 (+0.22), ADXS: 7.18 (+0.06), OPHT: 51.11 (+0.12), LMNX: 15.45 (+0.02), ENTA: 33.30 (-0.44), ORPN: 7.17 (+0.04), EVOK: 5.41 (-0.10), RCII: 30.49 (+0.92), SCYX: 9.48 (+0.07), SSYS: 67.16 (-0.34), AKBA: 9.32 (+0.51), VBLT: 14.11 (+0.24)
Evoke Pharma Outlines Progress on Clinical Program
GlobeNewswire - Mon Feb 02, 9:05AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today provided an update on its clinical program for EVK-001, its novel metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
EVOK: 5.41 (-0.10)
Patient enrollment sub par in Phase 3 study of Evoke's lead product candidate
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 8:27AM CST
EVOK: 5.41 (-0.10)
Impax Soars on FDA Nod of Parkinson's Disease Drug Rytary - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 3:39PM CST
Impax's shares hit a 52-week high with the FDA approval of Parkinson's disease drug, Rytary.
IPXL: 39.51 (+0.69), EVOK: 5.41 (-0.10), MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 11:47AM CST
CY: 14.76 (+0.01), QDEL: 25.18 (+0.35), WLT: 1.09 (+0.05), VNCE: 24.68 (+0.22), ISNS: 2.49 (+0.03), VII: 1.47 (-0.02), NTLS: 5.19 (+0.05), MFRM: 62.22 (-0.12), GSAT: 2.40 (+0.08), MOLG: 2.46 (+0.03), EVOK: 5.41 (-0.10), IDRA: 4.10 (-0.14), SCVL: 24.02 (-0.06), VGGL: 1.77 (-0.08), MIXT: 5.69 (+0.08), ENVI: 1.45 (-0.01), REI: 10.00 (+0.27), TRX: 0.57 (+0.01), DGLY: 11.50 (-0.40), CODE: 35.99 (+0.03)
Evoke clears another hurdle on its path to NDA for metoclopramide nasal spray
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 8:05AM CST
EVOK: 5.41 (-0.10)
Evoke Pharma's EVK-001 Showed No QT Prolongation in Thorough ECG (TQT) Study
GlobeNewswire - Tue Dec 02, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced results from an electrocardiogram (ECG) study that assessed the potential of metoclopramide nasal spray (EVK-001) to increase the cardiac QT and corrected QT (QTc) interval across a range of plasma concentrations. The study was conducted to satisfy a safety requirement by the U.S. Food and Drug Administration (FDA) in support of the submission of a New Drug Application (NDA) for EVK-001, an investigational medication for relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The study met the pre-specified primary endpoint, demonstrating that EVK-001, at therapeutic and supratherapeutic doses, did not prolong the QT/QTc interval in healthy subjects.
EVOK: 5.41 (-0.10)
Evoke Pharma to Present at LD Micro Conference
GlobeNewswire - Tue Nov 25, 7:31AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, will host an investor presentation on Thursday, December 4, 2014 at 11:30AM PT at the LD Micro Main Event VII Conference. The conference is being held December 2-4, 2014 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
EVOK: 5.41 (-0.10)
Dr. Kenneth J. Widder Joins Quidel's Board of Directors
Marketwired - Wed Nov 19, 3:39PM CST
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Kenneth J. Widder, M.D. has agreed to join Quidel's Board of Directors, effective immediately. Quidel's Board has been expanded to eight members.
EVOK: 5.41 (-0.10), QDEL: 25.18 (+0.35)
Supernus Pharmaceuticals (SUPN) in Focus: Stock Up 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:32AM CST
Supernus Pharmaceuticals, Inc. (SUPN) was a big mover last session, as the company saw its shares nearly 10% on the day.
EVOK: 5.41 (-0.10), AKRX: 47.28 (-0.25), SUPN: 8.80 (+0.22)
Evoke Pharma's (EVOK) CEO Dave Gonyer on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 8:04PM CST
EVOK: 5.41 (-0.10)
Evoke Pharma beats by $0.15
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:10PM CST
EVOK: 5.41 (-0.10)
Evoke Pharma Reports Third Quarter 2014 Results
GlobeNewswire - Thu Nov 13, 3:09PM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2014.
EVOK: 5.41 (-0.10)